Tirzepatide Associated With Lower Mortality Risk Than Dulaglutide in T2D

Summary: A new study looked at adults with Type 2 diabetes and heart disease to see which medications work best. Researchers compared three popular drugs: tirzepatide, dulaglutide, and semaglutide. They found that patients taking tirzepatide had a lower risk of death and fewer hospital visits for pneumonia compared to those taking dulaglutide. However, when comparing tirzepatide to semaglutide, the risks for major heart issues were about the same. This information helps doctors and patients choose the best treatment for long-term health.

For more details, see rssapp-pulmonologyadvisor-com at pulmonologyadvisor.com/news/tirzepatide-associated-with-lower-mortality-risk-than-dulaglutide-in-t2d/ (opens in new tab)